Post Trial Access of Modakafusp Alfa (TAK-573) monotherapy or in Combination for the Treatment of Advanced Multiple Myeloma
Categories (click each to see list of all clinical trials associated with that category): Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Closed
Phase: N/A (Cancer Control)
Principal Investigator: Holstein, Sarah
Contact Information:
Marnee Strege
+1 402-559-8155
marnee.strege@unmc.edu
Summary
To provide Post Trial Access (PTA) to Modakafusp Alfa for patients who are benefiting from treatment on a qualifying clinical trial.